Regulatory/Agencies/TGA
🇦🇺Therapeutic Goods Administration

TGA NAMs Framework

Australia's TGA accepts NAMs through the ACSS consortium work-sharing and mutual recognition agreements with FDA, EMA, and Health Canada, enabling efficient global regulatory alignment.

ACSS
Consortium Member
C2C
Comparable Pathway
2024
NAMs Policy
3Rs
NHMRC Code
Written by J Radler | Patient Analog
Last updated: January 2025

Regulatory Highlights

  • Current regulatory framework and acceptance pathways
  • Compliance requirements for NAMs submissions
  • International harmonization through ICH guidelines
  • Practical guidance for regulatory strategy

Australia's Regulatory Approach to NAMs

The Therapeutic Goods Administration (TGA) takes a progressive approach to NAMs acceptance, leveraging international partnerships and work-sharing arrangements to enable efficient adoption of innovative methodologies.

Australia's National Health and Medical Research Council (NHMRC) mandates the 3Rs principles in the Australian Code for the Care and Use of Animals for Scientific Purposes, providing strong support for NAMs development.

ACSS Consortium Partnership

TGA is a founding member of the ACSS (Australia-Canada-Singapore-Switzerland) consortium, enabling:

  • Work-Sharing Reviews: Shared assessment of NAMs qualification packages across member agencies
  • Comparable Overseas Regulator (COR): Expedited pathways for NAMs approved by reference agencies
  • Joint Scientific Advice: Coordinated guidance on NAMs development programs

TGA NAMs Acceptance Mechanisms

  • Reference to FDA ISTAND qualification decisions
  • Recognition of EMA SAWP qualification opinions
  • ICH guideline-compliant NAMs automatically acceptable
  • Pre-submission scientific advice available

Australian NAMs Ecosystem

Australia has a growing NAMs research and development sector:

  • CSIRO: National science agency with organ-on-chip programs
  • University of Melbourne: Leading organoid research center
  • Monash University: Stem cell and tissue engineering expertise
  • Walter and Eliza Hall Institute: Disease modeling with organoids

Related Agencies

🇺🇸 FDA 🇪🇺 EMA 🇨🇦 Health Canada 🇸🇬 HSA Singapore

Frequently Asked Questions

TGA accepts NAMs data through ACSS consortium work-sharing and reference to FDA/EMA qualifications. Australia supports NAMs development through research funding and regulatory flexibility.
ACSS (Australia-Canada-Singapore-Switzerland) enables regulatory work-sharing among member agencies. NAMs qualified by one member receive expedited review by others, reducing regulatory burden.
Australian researchers at universities (Melbourne, Monash, UNSW) develop organ-on-chip and organoid technologies. CSIRO (national research agency) has active MPS programs.
TGA has mutual recognition arrangements with FDA and participates in international harmonization. NAMs accepted by FDA are generally viewed favorably by TGA with appropriate documentation.
Australian Code for Care and Use of Animals (NHMRC) requires 3Rs implementation. This supports NAMs adoption when scientifically validated as replacements for animal testing.

© 2025 Patient Analog. All rights reserved.

Educational content created by J Radler for the biotech and scientific community. Last updated: February 4, 2026.

Free to share for educational purposes with attribution.